STOCK TITAN
  1. Home
  2. News
  3. DMTTF

Small Pharma Inc - DMTTF STOCK NEWS

Welcome to our dedicated news page for Small Pharma (Ticker: DMTTF), a resource for investors and traders seeking the latest updates and insights on Small Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Small Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Small Pharma's position in the market.

News
Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
Rhea-AI Summary
Cybin completes acquisition of Small Pharma, creating the largest deuterated DMT program and intellectual property portfolio in the psychedelic drug development sector. Two advanced clinical programs for depression and anxiety disorders. Phase 2 safety and efficacy data expected in late 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
acquisition
-
News
Small Pharma Reports Fiscal Second Quarter 2024 Highlights
Rhea-AI Summary
Small Pharma shareholders vote in favor of Cybin's acquisition, creating an international clinical-stage leader in psychedelic-based therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
earnings
-
News
Small Pharma Obtains Final Order Approving Arrangement
Rhea-AI Summary
Small Pharma and Cybin announce final court approval for acquisition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.6%
Tags
none
News
Small Pharma Announces Voting Results from Annual General and Special Meeting of Shareholders
Rhea-AI Summary
Shareholders approve Cybin's acquisition of Small Pharma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.43%
Tags
none
-
News
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
Rhea-AI Summary
Small Pharma Inc. announces positive safety, tolerability, and efficacy data from its Phase Ib study on the interaction between SSRIs and SPL026 (DMT) in MDD patients. 100% of patients in the SSRI cohort responded to SPL026 with 92% in remission from depression. No differences in safety and tolerability between SSRI and non-SSRI cohorts. The potentially enhanced efficacy effect of a DMT-based treatment when administered with SSRIs could lead to greater therapeutic benefit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
none
-
News
Cybin to Acquire Small Pharma Inc.
Rhea-AI Summary
Cybin Inc. and Small Pharma Inc. have entered into a definitive arrangement agreement for Cybin to acquire all of Small Pharma's issued and outstanding securities in an all-share transaction. The exchange ratio implies consideration of approximately $0.10 per Small Pharma Share, representing a 43.6% premium. The combined entity will create an international clinical-stage leader in novel psychedelic therapeutics with the largest intellectual property portfolio in the sector. The transaction is expected to close in late October 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
acquisition
News
Cybin to Acquire Small Pharma Inc.
Rhea-AI Summary
Cybin to acquire Small Pharma in all-share transaction, creating a leader in psychedelic therapeutics. Small Pharma shareholders to receive 0.2409 Cybin Shares for each Small Pharma Share held, representing a 43.64% premium. Combined company will have the largest IP portfolio in the psychedelic drug development sector with 28 granted patents and 158 pending patents. Cybin expects to report Phase 2 safety and efficacy data for CYB003 in late 2023. Transaction expected to close in late October 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
acquisition
-
News
Small Pharma Reports Fiscal First Quarter 2024 Highlights
Rhea-AI Summary
Small Pharma Inc. has published its financial results for Q1 2023. Cash on hand is $13.2 million. The company completed dosing in its Phase Ib drug interaction study for SPL026 and expects results in Q3 2023. Results from the IM SPL026 Phase I study showed a mean psychedelic experience duration of approximately 45 minutes. SPL028 is currently dosing in a Phase I study with preliminary findings expected in Q4 2023. The company's IP portfolio has made significant progress with 26 patents granted and 95 patent applications pending.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.3%
Tags
earnings
-
News
Small Pharma Announces SPL028 R&D Strategy Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.29%
Tags
none
News
Small Pharma Announces Management Team Change
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.29%
Tags
none
Stock DMTTF logo
Small Pharma Inc

NYSE:DMTTF

DMTTF Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

DMTTF Stock Data

37.51M
335.77M
31.08%
0.67%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United Kingdom
London